CUSTOMER SERVICE:

OR +1 (800) 643-3426

MENU
Search
Advanced Search
MENU
My Order 0
My Quote My Quote
Search
Advanced Search
  • Baby Rabbit Complement Lyophilized

Baby Rabbit Complement Lyophilized

Complement is produced under controlled conditions from large pools of New Zealand White rabbits that are 21-28 days old. This provides a product that has low heterophile antibody activity for many applications, including use in bactericidal and opsonization assays.
Product Datasheet
Specifications
Lyophilized powder
-70°C or below
Learn more

Product Code: Select size

Custom/Bulk request

SEE Bulk Requirements

Bulk Requirements for Human Serum
From
 $34.00
Lead time on this item is currently: 2-4 Weeks

Need help? Ask a Specialist Contact Us OR +1 (800) 643-3426

Product Overview
Product Overview
Storage Conditions: -70°C or below
Shipping Conditions: Dry ice
Species: Rabbit
Application Notes: Suitable for functional antibody assays (SBA-Serum Bactericidal Assay, MOPA/OPA- Multiplexed /Opsonophagocytic Killing Assay) for vaccine evaluation. Complement components are extremely heat-sensitive; for best results, thaw complement on ice or in a cold water bath. Aliquots may be made and frozen at -70°C or below. Avoid multiple freeze-thaw cycles. When a working aliquot is thawed, do not re-freeze remaining complement, but discard it.
Guarantee: Product quality is guaranteed to meet Pel-Freez Biologicals’ specifications for 1 year from the date of receipt by the customer as long as the product is stored in accordance with the indicated storage conditions.
Testing: Hemolytic: Titer ≥ 1:16 Endotoxin: ≤ 1.0 EU/mL Sterility: Passed, 14 day sterility testing. Mycoplasma: Negative Viral: Negative
Product Attributes: Complement
Packaging: Glass vial
Donor Sex: Mixed
Product Types: Complement
Product Applications

Documents & Datasheets

Product Datasheet
Datasheet for 31064 Rabbit 3-4 Week Complement Lyophilized Rev 01
Safety Datasheet
SDS for 31064 Rabbit Complement 3-4 Week Lyophilized

Product References

Human IgM inhibits the formation of titan-like cells in Cryptococcus neoformans

Nuria Trevijano-Contador et al. Human IgM inhibits the formation of titan-like cells in cryptococcus neoformans. Infect. Immun. 88, (2020).
Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)

Kwon, J.-C. et al. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). Animal Cells Syst. (Seoul). 1–13 (2021).
Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes

Salehi, S., Hohn, C. M., Penfound, T. A. & Dale, J. B. Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes . mSphere 3, (2018).
Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella

Ramachandran, G. et al. Functional activity of antibodies directed towards Flagellin proteins of non-typhoidal Salmonella. PLoS One 11, 151875 (2016).
Cryptococcus neoformans Coinfection Dampens the TNF-α Response in HIV-1-Infected Human THP-1 Macrophages

Kalem, M. C., Humby, M. S., Wohlfert, E. A., Jacobs, A. & Panepinto, J. C. Cryptococcus neoformans Coinfection Dampens the TNF-α Response in HIV-1-Infected Human THP-1 Macrophages. mSphere 6, (2021).
Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus …

St. Michael, F. et al. Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans. Glycoconj. J. 35, 53–64 (2018).
Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA

Gu, H. et al. Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA. Front. Cell. Infect. Microbiol. 8, 172 (2018).
Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice

Zhang, X. et al. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice. Vaccine 36, 1047–1054 (2018).
Quality improvement of capsular polysaccharide in streptococcus pneumoniae by purification process optimization

Lee, C. et al. Quality Improvement of Capsular Polysaccharide in Streptococcus pneumoniae by Purification Process Optimization. Front. Bioeng. Biotechnol. 8, (2020).
Validity of Enzyme-Linked Immunosorbent Assay (ELISA) as a correlate of protection of meningococcal C conjugated vaccine in adolescents with HIV infection

Daniela Vinhas, B. et al. Validity of Enzyme-Linked Immunosorbent Assay (ELISA) as a correlate of protection of meningococcal C conjugated vaccine in adolescents with HIV infection. J. Vaccines Immunol. 6, 001–007 (2020).
Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus

Choi, M. J. et al. Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus. Hum. Vaccines Immunother. 16, 1338–1344 (2020).
Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease

Scully, I. L. et al. Performance of a four-antigen staphylococcus aureus vaccine in preclinical models of invasive S. aureus disease. Microorganisms 9, 1–13 (2021).
A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.

Ozdilek, A. et al. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies. MBio (2021).
Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations against Seven Streptococcus agalactiae Serotypes

Lee, J. H., Kim, H. W., Cha, J. & Kim, K. H. Opsonophagocytic antibodies of intravenous immunoglobulin preparations against seven streptococcus agalactiae serotypes. Pediatr. Infect. Vaccine 28, 21–30 (2021).
An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera

McGregor, R., Jones, S., Jeremy, R. M., Goldblatt, D. & Moreland, N. J. An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera. in Methods in Molecular Biology vol. 2136 323–335 (Humana Press Inc., 2020).
Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines

Xu, H. et al. Expression of bordetella pertussis antigens fused to different vectors and their effectiveness as vaccines. Vaccines 9, (2021).
Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.

McGuinness, D. et al. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine (2021).
Related Products